Teva Pharmaceutical Industries (NYSE:TEVA) shares continued gains for seven straight sessions, as the stock closed 1% higher ...

NYSE:TEVA 1 Year Share Price vs Fair Value Explore Teva Pharmaceutical Industries's Fair Values from the Community ...

We came across a bullish thesis on Teva Pharmaceutical Industries Limited on Kontra Investments’s Substack by Kontra. In this ...

Teva Pharmaceutical Industries reported a better than expected increase in second-quarter profit on Wednesday, helped by a 26 ...

Teva Pharmaceutical Industries Ltd. announced an acceleration phase of its “Pivot to Growth” strategy aimed at transforming the company into a leading global biopharmaceutical player.

Barclays reduced their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th.

Teva Pharmaceutical Industries says second-quarter profit rose 5 percent, to $241 million, while Ivax Corp, drug company that Teva plans to buy, says its earnings fell to $45.6 million (S) ...

Teva Pharmaceutical Industries announced early results of its tender offers for various series of notes, increasing total purchase caps. Quiver AI Summary Teva Pharmaceutical Industries Ltd ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is engaged in developing, manufacturing, marketing, and distributing generic medicines, specialty medicines, and biopharmaceutical products.